belantamab mafodotin + GSK3174998

Belantamab mafodotin + GSK3174998 is an investigational **combination therapy** for relapsed/refractory multiple myeloma, currently being studied in clinical trials. **Belantamab mafodotin** (BLENREP, also known as GSK2857916) is an antibody-drug conjugate (ADC) consisting of a humanized anti–B-cell maturation antigen (BCMA) monoclonal antibody linked to mafodotin, a microtubule inhibitor. This ADC targets BCMA on malignant plasma cells, delivering mafodotin to induce cytotoxicity, and stimulates immunogenic cell death with additional immune-mediated anti-tumor effects such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). **GSK3174998** is a fully human monoclonal antibody acting as an agonist of OX40 (CD134), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immune responses by increasing T-cell activation and proliferation. The rationale for the combination is to potentiate the immunomodulatory and cytotoxic effects in multiple myeloma by simultaneously targeting tumor cells and stimulating immune effector cells[1][3].

Other names

belamafOX40 agonist antibodyOX-40 agonist antibodyOX 40 agonist antibody